Goldman Sachs
ACTU

Goldman Sachs’s Actuate Therapeutics ACTU Stock Holding History

Goldman Sachs’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34K Buy
+12,408
New +$51.4K ﹤0.01% 6328
2025
Q2 		– Sell
-22,358
Closed -$151K – 6520
2025
Q1 		$151K Buy
22,358
+11,105
+99% +$89.2K ﹤0.01% 5700
2024
Q4 		$89.6K Buy
+11,253
New +$91.8K ﹤0.01% 5782

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's ACTU Position: Q1 2026 in Review

Goldman Sachs opened a new position in Actuate Therapeutics (ACTU) in Q1 2026: 12,408 shares worth $34K. The stake represents ﹤0.01% of the portfolio and ranks #6328 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in ACTU as recently as Q1 2025.

Goldman Sachs first reported a position in ACTU in Q4 2024 and has held it in 3 quarters since. The position peaked at $151K in Q1 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • Goldman Sachs held 12,408 shares of Actuate Therapeutics worth $34K as of Q1 2026.
  • Actuate Therapeutics was a new Goldman Sachs position in Q1 2026.
  • Actuate Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6328 holding.
  • Goldman Sachs first reported a position in Actuate Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Goldman Sachs's Actuate Therapeutics position peaked at $151K in Q1 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.